文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

极低出生体重儿动脉导管未闭手术闭合后的神经感觉障碍:早产儿吲哚美辛预防试验的结果

Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms.

作者信息

Kabra Nandkishor S, Schmidt Barbara, Roberts Robin S, Doyle Lex W, Papile Luann, Fanaroff Avroy

机构信息

Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.

出版信息

J Pediatr. 2007 Mar;150(3):229-34, 234.e1. doi: 10.1016/j.jpeds.2006.11.039.


DOI:10.1016/j.jpeds.2006.11.039
PMID:17307535
Abstract

OBJECTIVES: To determine whether surgical closure of a patent ductus arteriosus (PDA) is a risk factor for bronchopulmonary dysplasia (BPD), severe retinopathy of prematurity (ROP), and neurosensory impairment in extremely low birth weight (ELBW) infants. STUDY DESIGN: We studied 426 infants with a symptomatic PDA, 110 of whom underwent PDA ligation and 316 of whom received medical therapy only. All infants participated in the multicenter Trial of Indomethacin Prophylaxis in Preterms (TIPP) and were observed to a corrected age of 18 months. RESULTS: Of the 95 infants who survived after PDA ligation, 50 (53%) had neurosensory impairment, compared with 84 of the 245 infants (34%) who survived after receiving only medical therapy (adjusted odds ratio, 1.98; 95% CI, 1.18-3.30; P = .0093). BPD (adjusted odds ratio, 1.81; 95% CI, 1.09-3.03; P = .023) and severe ROP (adjusted odds ratio, 2.20; 95% CI, 1.19-4.07; P = .012) were also more common after surgical PDA closure. CONCLUSIONS: PDA ligation may be associated with increased risks of BPD, severe ROP, and neurosensory impairment in ELBW infants.

摘要

目的:确定动脉导管未闭(PDA)手术闭合是否为极早产儿(ELBW)发生支气管肺发育不良(BPD)、重度早产儿视网膜病变(ROP)及神经感觉功能障碍的危险因素。 研究设计:我们研究了426例有症状性PDA的婴儿,其中110例行PDA结扎术,316例仅接受药物治疗。所有婴儿均参与了早产儿吲哚美辛预防多中心试验(TIPP),并观察至矫正年龄18个月。 结果:PDA结扎术后存活的95例婴儿中,50例(53%)有神经感觉功能障碍,而仅接受药物治疗后存活的245例婴儿中有84例(34%)出现此情况(校正比值比为1.98;95%可信区间为1.18 - 3.30;P = 0.0093)。手术闭合PDA后,BPD(校正比值比为1.81;95%可信区间为1.09 - 3.03;P = 0.023)和重度ROP(校正比值比为2.20;95%可信区间为1.19 - 4.07;P = 0.012)也更常见。 结论:PDA结扎术可能与ELBW婴儿发生BPD、重度ROP及神经感觉功能障碍的风险增加有关。

相似文献

[1]
Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms.

J Pediatr. 2007-3

[2]
Analysis of outcome in 298 extremely low-birth-weight infants with patent ductus arteriosus.

J Pediatr Surg. 2009-1

[3]
Factors affecting successful closure of hemodynamically significant patent ductus arteriosus with indomethacin in extremely low birth weight infants.

World J Pediatr. 2008-5

[4]
Prophylactic surgical ligation of patent ductus arteriosus for prevention of mortality and morbidity in extremely low birth weight infants.

Cochrane Database Syst Rev. 2008-1-23

[5]
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.

Cochrane Database Syst Rev. 2008-1-23

[6]
Association of Patent Ductus Arteriosus Ligation With Death or Neurodevelopmental Impairment Among Extremely Preterm Infants.

JAMA Pediatr. 2017-5-1

[7]
Variation and comparative effectiveness of patent ductus arteriosus pharmacotherapy in extremely low birth weight infants.

J Neonatal Perinatal Med. 2014-1-1

[8]
Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP).

J Pediatr. 2006-6

[9]
Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms.

Pediatrics. 2008-2

[10]
Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias.

J Pediatr. 2012-6-14

引用本文的文献

[1]
Evaluating the efficacy and safety of milrinone for prevention of post-patent ductus arteriosus closure syndrome (the MIDAS trial) in extremely preterm infants: a multicentre, double-masked, randomised, placebo-controlled trial.

BMJ Open. 2025-8-26

[2]
Respiratory Outcomes After Transcatheter vs Surgical Patent Ductus Arteriosus Closure in Preterm Infants.

JAMA Netw Open. 2025-6-2

[3]
Largest Single-Center Experience Using the Micro Vascular Plug (MVP) for Transcatheter Closure of Premature Patent Ductus Arteriosus.

Pediatr Cardiol. 2025-3-27

[4]
Factors Predicting Spontaneous Closure of Patent Ductus Arteriosus in Very Low Birth Weight Neonates.

Cureus. 2024-8-30

[5]
Improved Outcomes following a Conservative Approach to Hemodynamically Significant Patent Ductus Arteriosus: A Comparison across Two Periods.

Cardiology. 2025

[6]
A Global Perspective on PDA Management in the Extremely Premature: Shifting Trend Toward Transcatheter Closure.

J Soc Cardiovasc Angiogr Interv. 2023-5-19

[7]
Strategies for the prevention of bronchopulmonary dysplasia.

Front Pediatr. 2024-7-24

[8]
Risk factors for PDA ligation and neurodevelopmental outcomes at corrected 18-24 months in very low birth weight infants.

BMC Pediatr. 2024-5-31

[9]
Who Still Gets Ligated? Reasons for Persistence of Surgical Ligation of the Patent Ductus Arteriosus Following Availability of Transcatheter Device Occlusion for Premature Neonates.

J Cardiovasc Dev Dis. 2024-4-23

[10]
Should we "eliminate" PDA shunt in preterm infants? A narrative review.

Front Pediatr. 2024-2-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索